Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
Portfolio Pulse from Benzinga Newsdesk
Protagenic Therapeutics reported safety data from the single dose portion of its Phase 1 trial involving PT00114, with no clinically-relevant adverse events. The multiple dose portion of the trial is set to commence.
May 22, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagenic Therapeutics reported positive safety data from the single dose portion of its Phase 1 trial for PT00114, with no clinically-relevant adverse events. The multiple dose portion of the trial will now commence.
The positive safety data from the single dose portion of the Phase 1 trial is a significant milestone for Protagenic Therapeutics. The absence of clinically-relevant adverse events is likely to boost investor confidence and positively impact the stock price in the short term as the company progresses to the multiple dose portion of the trial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100